{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-099343","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.590913+00:00","generated_at":"2026-05-17T03:57:50.332883+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Gain Therapeutics hosts KOL event highlighting emerging GT-02287 Parkinson's data","bullets":["Virtual KOL event on Oct 14, 2025 featured Dr. Karl Kieburtz (Univ. of Rochester) and Dr. Kenneth Marek (Institute for Neurodegenerative Disorders).","Presentation focused on biomarkers, clinical endpoints, and path to disease modification for GT-02287.","GT-02287 is a GCase-targeting small molecule for Parkinson's disease; emerging data was contextualized.","Slides from the event were furnished as an exhibit; no new quantitative data or financial guidance provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-099343","json":"https://secwatch.observer/filing/0001104659-25-099343.json","markdown":"https://secwatch.observer/filing/0001104659-25-099343.md","text":"https://secwatch.observer/filing/0001104659-25-099343.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465925099343/0001104659-25-099343-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465925099343/tm2528732d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:57:50.332883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}